Inmune Bio Inc., of La Jolla, Calif., filed with the SEC to offer a minimum of 1 million shares for gross proceeds of $8 million and a maximum of up to 2.5 million shares for gross proceeds of $20 million. Proceeds will support R&D activities of its Inkmune cancer program and other immuno-oncology efforts.